Their strategy of utilizing NIH funding for most of the pre-work has been smart, IMO. Their patents and all the information generated from both the OSA and Epilepsy/Pain programs are very valuable... Big money will enter once all the pre-work is completed. It is rare to have two extremely promising programs advancing to critical IND funding stages around the same time. It feels like the OSA is just awaiting maybe some more funding and possibly some initial testing of the formulation to launch full scale phase 3, which will immediately rocket the valuation here. And the CEO essentially indicated they are in final tier 3 of NIH program for pain and projecting to get grant money and hopefully large scale funding/partnership to move into full scale human trials.
Exciting time period to be on the cusp and accumulate so cheaply before multiple potential material events....
News 
Market Data 
Discover 
